Burimamide is an antagonist at the H2 and H3 histamine receptors.

At physiological pH, it is largely inactive as an H2 antagonist,[1] but its H3 affinity is 100x higher.

Burimamide was first developed by scientists at Smith, Kline & French (SK&F; now GlaxoSmithKline) in their intent to develop a histamine antagonist for the treatment of peptic ulcers.

[2] The discovery of burimamide ultimately led to the development of cimetidine (Tagamet).

[2] This drug article relating to the gastrointestinal system is a stub.